Journal of Vaccines & Vaccination

Journal of Vaccines & Vaccination
Open Access

ISSN: 2157-7560

Michael J Ciesielski

Michael J Ciesielski
Roswell Park Cancer Institute,
Elm & Carlton Streets, Buffalo, NY 14263
Tanzania

Publications
  • Review Article
    Survivin as a Cancer Vaccine Target
    Author(s): Michael J Ciesielski, Jingxin Qiu and Robert A FenstermakerMichael J Ciesielski, Jingxin Qiu and Robert A Fenstermaker

    Survivin expression is associated with a poor prognosis in many cancers. While survivin is being studied as a potentially important target for cancer therapy, its many biological functions in both normal and cancerous cells remain to be fully elucidated. There are at least six specific survivin splice variants that have been identified to date which appear to be self-regulating and may have distinct functions. Several survivin peptide vaccines are currently under development by different groups. Survivin vaccine strategies for the most part have focused upon particular regional epitopes of the molecule that are bound by MHC class I and can lead to a cytotoxic T cell response. Immunotherapy targeting survivin is still at an early stage of development; however, several agents are progressing through early phase clinical trials. Recent studies using SurVaxM, a multi-epitope cryptic pepti.. Read More»
    DOI: 10.4172/2157-7560.1000230

    Abstract PDF

Relevant Topics

Top